BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32712923)

  • 1. Design and Evaluation of AgoshRNAs with 3'-Terminal HDV Ribozymes to Enhance the Silencing Activity.
    Berkhout B; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():225-252. PubMed ID: 32712923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the loop size and nucleotide composition on AgoshRNA biogenesis and activity.
    Herrera-Carrillo E; Harwig A; Berkhout B
    RNA Biol; 2017 Nov; 14(11):1559-1569. PubMed ID: 28569591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of HIV-1 by AgoshRNA molecules.
    Herrera-Carrillo E; Harwig A; Berkhout B
    Gene Ther; 2017 Aug; 24(8):453-461. PubMed ID: 28553929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of a 3' Terminal Ribozyme on AgoshRNA Biogenesis and Activity.
    Herrera-Carrillo E; Gao Z; Berkhout B
    Mol Ther Nucleic Acids; 2019 Jun; 16():452-462. PubMed ID: 31048184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards Antiviral shRNAs Based on the AgoshRNA Design.
    Liu YP; Karg M; Herrera-Carrillo E; Berkhout B
    PLoS One; 2015; 10(6):e0128618. PubMed ID: 26087209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic insights on the Dicer-independent AGO2-mediated processing of AgoshRNAs.
    Liu YP; Karg M; Harwig A; Herrera-Carrillo E; Jongejan A; van Kampen A; Berkhout B
    RNA Biol; 2015; 12(1):92-100. PubMed ID: 25826416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward optimization of AgoshRNA molecules that use a non-canonical RNAi pathway: variations in the top and bottom base pairs.
    Herrera-Carrillo E; Harwig A; Berkhout B
    RNA Biol; 2015; 12(4):447-56. PubMed ID: 25747107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of AgoshRNA maturation and loading into Ago2.
    Harwig A; Kruize Z; Yang Z; Restle T; Berkhout B
    PLoS One; 2017; 12(8):e0183269. PubMed ID: 28809941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting AgoshRNA activity by optimized 5'-terminal nucleotide selection.
    Gao Z; Berkhout B; Herrera-Carrillo E
    RNA Biol; 2019 Jul; 16(7):890-898. PubMed ID: 30991896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribozyme-enhanced single-stranded Ago2-processed interfering RNA triggers efficient gene silencing with fewer off-target effects.
    Shang R; Zhang F; Xu B; Xi H; Zhang X; Wang W; Wu L
    Nat Commun; 2015 Oct; 6():8430. PubMed ID: 26455506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection.
    Herrera-Carrillo E; Berkhout B
    PLoS One; 2017; 12(5):e0177935. PubMed ID: 28542329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
    Berkhout B; Gao Z; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dicer-independent processing of short hairpin RNAs.
    Liu YP; Schopman NC; Berkhout B
    Nucleic Acids Res; 2013 Apr; 41(6):3723-33. PubMed ID: 23376931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of the 5΄-terminal nucleotide on AgoshRNA activity and biogenesis: importance of the polymerase III transcription initiation site.
    Herrera-Carrillo E; Gao ZL; Harwig A; Heemskerk MT; Berkhout B
    Nucleic Acids Res; 2017 Apr; 45(7):4036-4050. PubMed ID: 27928054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity.
    Herrera-Carrillo E; Harwig A; Liu YP; Berkhout B
    RNA; 2014 Sep; 20(9):1410-8. PubMed ID: 25035295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep Sequence Analysis of AgoshRNA Processing Reveals 3' A Addition and Trimming.
    Harwig A; Herrera-Carrillo E; Jongejan A; van Kampen AH; Berkhout B
    Mol Ther Nucleic Acids; 2015 Jul; 4(7):e247. PubMed ID: 26172504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs.
    Liu YP; von Eije KJ; Schopman NC; Westerink JT; ter Brake O; Haasnoot J; Berkhout B
    Mol Ther; 2009 Oct; 17(10):1712-23. PubMed ID: 19672247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.
    Lainé S; Scarborough RJ; Lévesque D; Didierlaurent L; Soye KJ; Mougel M; Perreault JP; Gatignol A
    RNA Biol; 2011; 8(2):343-53. PubMed ID: 21422817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 96 shRNAs designed for maximal coverage of HIV-1 variants.
    McIntyre GJ; Groneman JL; Yu YH; Jaramillo A; Shen S; Applegate TL
    Retrovirology; 2009 Jun; 6():55. PubMed ID: 19497094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines.
    Börner K; Niopek D; Cotugno G; Kaldenbach M; Pankert T; Willemsen J; Zhang X; Schürmann N; Mockenhaupt S; Serva A; Hiet MS; Wiedtke E; Castoldi M; Starkuviene V; Erfle H; Gilbert DF; Bartenschlager R; Boutros M; Binder M; Streetz K; Kräusslich HG; Grimm D
    Nucleic Acids Res; 2013 Nov; 41(21):e199. PubMed ID: 24049077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.